Refractive surgeons are likely to enjoy success with monovision for presbyopia if they aim for a maximum of 1.50 D of residual myopia in the non-dominant eye, exclude patients with pre-existing strabismus, and monitor for signs of strabismus.
Crosslinking meets the previously unmet needs of progressive keratoconus patients and provides an opportunity to increase engagement with optometrists, explain John Berdahl, MD, and George O. Waring IV, MD.
William Fredette, MD, discusse the results of two trials published in Opthalmology, which indicate that the combination of Verteporfin Photodynamic Therapy plus ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularization secondary to AMD. Video provided by The Doctor's Channel.
As dry eye syndrome (DES) affects more and more patients over the next 10 years, pharmaceutical companies are expecting to expand their clinical products globally to treat the condition, thus tripling the market’s global revenue over the next decade.
Researchers have identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigments (RP).
The Welch Allyn facility in Beaverton, OR, earned Leadership in Energy and Environmental Design (LEED) certification from the U.S. Green Building Council.
Glaucoma may be a significant predictor of depression, according to research published in the American Journal of Ophthalmology.
A trifocal diffractive intraocular lens (FineVision IOL, PhysIOL) reduces spectacle dependence after cataract surgery and provides patient satisfaction.
Ocular Therapeutix Inc. is initiating a phase II clinical trial of OTX-TP2, a 2-month travoprost punctum plug for treating ocular hypertension and glaucoma.
Gevokizumab, an IL-1 beta-modulating antibody from XOMA Corp., has received FDA orphan drug designation for the treatment of several types of non-infectious uveitis.